Parameter | Zishen Pingchan (n = 89) | Placebo (n = 87) | p-value |
---|---|---|---|
Male gender; n (%) | 42 (47.7%) | 45 (51.1%) | 0.651b |
Age; years mean ± SD | 68.1 ± 8.0 | 66.4 ± 9.8 | 0.203a |
Duration of PD; months mean ± SD | 92.4 ± 48.1 | 80.8 ± 46.9 | 0.196a |
MMSE score; median (IQR) | 29 (27, 30) | 29 (27, 30) | 0.765c |
UPDRS-III; mean ± SD | 23.98 ± 11.86 | 23.93 ± 11.14 | 0.979a |
LED; mean ± SD | 246.38 ± 123.90 | 234.40 ± 141.63 | 0.224a |
Hoehn-Yahr stage; n (%) | Â | Â | 0.949b |
Stage 1 Stage 1.5 Stage 2 Stage 2.5 Stage 3 Stage 4 | 11 (12.4%) 5 (5.6%) 43 (48.3%) 9 (10.1%) 20 (22.5%) 1 (1.1%) | 8 (9.2%) 7 (8.0%) 42 (48.3%) 9 (10.3%) 19 (21.8%) 2 (2.3%) | Â |